BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With SSc-ILD on the cusp of regulatory approval following clos
 ely behind Pirfenidone’s breakthrough therapy designation to treat uILD e
 arlier this year\, and investment pouring across multiple ILD phenotypes\
 , the window of therapeutic opportunity to develop clinically defining dr
 ugs to treat interstitial lung disease is well and truly open.\n\nThe tim
 ely 2nd ILD Summit will siphon critical insights from experts at Pfizer\,
  Genentech\, Novartis\, Boehringer Ingelheim and Pieris Pharmaceuticals t
 o help you to catalyze a new wave of therapies against Scleroderma\, Sarc
 oidosis\, COP\, CT-ILDs and more.\n\nWith 3 unique days of dedicated scie
 ntific content - from discovering how to strategically optimize your appr
 oach to treating inflammatory vs fibrotic ILDs to learning how to leverag
 e clinical trials to identify novel outcomes and investigating the transf
 ormative power of machine learning for ILD imaging - this is the perfect 
 intensive crash course for experts across your team to get up to speed wi
 th the latest ILD developments.\n\nJoin 20+ brand new speakers and 150+ d
 rug developers from leading companies online to uncover the secrets behin
 d developing industry defining ILD therapies\, tailor the experience to m
 eet your needs and supercharge your ILD drug development approach.\n
DTEND:20220309T170500
DTSTAMP:20260512T232947Z
DTSTART:20220307T090000
LOCATION:Online\, \,
SEQUENCE:0
SUMMARY:With SSc-ILD on the cusp of regulatory approval following closely 
 behind Pirfenidone’s breakthrough therapy designation to treat uILD earli
 er this...
UID:74509f3b-037d-414e-888b-5278b1c936f2
END:VEVENT
END:VCALENDAR